I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

HNSCC afatinib clinical trials

Afatinib* is currently being investigated in Phase III trials of patients with head and neck squamous cell carcinoma (HNSCC), an area of focus in which there is a high unmet need for effective treatments.

The following table shows the clinical trials of afatinib in head and neck cancer; you can find links to further information on this site and published papers.

Filter by:

LUX-Head & Neck 3

Phase III

recruiting

Recurrent and/or metastatic HNSCC; second line or later

Afatinib vs methotrexate

Patients who have been pre-treated with platinum-based chemotherapy (second-line)

Related information

Head and neck squamous cell carcinoma in focus

Our current understanding of the characteristic features and biology of HNSCC and the challenges in its clinical management

HNSCC educational slide deck

An introductory resource on HNSCC that discusses epidemiology, risk factors, diagnosis, staging and treatment options

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.